Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Urinary Bladder Diseases"
Show Display Options
Rank Status Study
1 Recruiting Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Condition: Bladder Cancer
Interventions: Biological: TICE Bacillus Calmette-Guerin (BCG);   Biological: PANVAC
2 Recruiting Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
Conditions: Malignant Reproductive System Neoplasm;   Malignant Urinary System Neoplasm;   Metastatic Urethral Neoplasm;   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Progressive Neoplastic Disease;   Recurrent Bladder Carcinoma;   Recurrent Urethra Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Regional Urothelial Carcinoma of the Renal Pelvis and Ureter;   Solid Neoplasm;   Stage III Bladder Urothelial Carcinoma;   Stage III Urethral Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Urethral Cancer;   Urethral Urothelial Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab

Indicates status has not been verified in more than two years